Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase

  1. Kathrin Gottlob1,
  2. Nathan Majewski1,
  3. Scott Kennedy1,4,
  4. Eugene Kandel1,
  5. R. Brooks Robey2,3, and
  6. Nissim Hay1,5
  1. 1Department of Molecular Genetics; 2Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60607, USA; 3Veterans Administration, Chicago Healthcare System, West Side Division, Chicago, Illinois 60607, USA

Abstract

The serine/threonine kinase Akt/PKB is a major downstream effector of growth factor–mediated cell survival. Activated Akt, like Bcl-2 and Bcl-xL, prevents closure of a PT pore component, the voltage-dependent anion channel (VDAC); intracellular acidification; mitochondrial hyperpolarization; and the decline in oxidative phosphorylation that precedes cytochrome c release. However, unlike Bcl-2 and Bcl-xL, the ability of activated Akt to preserve mitochondrial integrity, and thereby inhibit apoptosis, requires glucose availability and is coupled to its metabolism. Hexokinases are known to bind to VDAC and directly couple intramitochondrial ATP synthesis to glucose metabolism. We provide evidence that such coupling serves as a downstream effector function for Akt. First, Akt increases mitochondria-associated hexokinase activity. Second, the antiapoptotic activity of Akt requires only the first committed step of glucose metabolism catalyzed by hexokinase. Finally, ectopic hexokinase expression mimics the ability of Akt to inhibit cytochrome c release and apoptosis. We therefore propose that Akt increases coupling of glucose metabolism to oxidative phosphorylation and regulates PT pore opening via the promotion of hexokinase-VDAC interaction at the outer mitochondrial membrane.

Keywords

Footnotes

  • 4 Present address: Department of Molecular Biology, MGH and Harvard Medical School, Boston, MA 02114, USA.

  • 5 Corresponding author.

  • E-MAIL nhay{at}uic.edu; FAX (312) 355-2032.

  • Article and publication are at www.genesdev.org/cgi/doi/10.1101/gad.889901.

    • Received February 21, 2001.
    • Accepted April 9, 2001.
| Table of Contents

Life Science Alliance